Assoc Prof of Med, GI with IBD focus @MayoClinic 🐊 | via @AUB_Lebanon @PittGIM @PittGILiverNutr | Chair of @AmerGastroAssn CPUC | ❤️research🧐🔬 to 📈👫Outcome
Hospitalized patients with #IBD from
@AmerGastroAssn
1-IBD Workup
2-Endoscopy: Staging + CMV rule out
3-Progression: IV steroid (for uncontrolled) + Daily CRP
4-Assessment: Medical/Surgical rescue (for unresponsive) or Transition to PO (for responsive)
https://t.co/fNzBD1T6mE
After years of living with Crohn's disease and trying treatments that didn't work, Amy Marshak felt she was running out of options. The chronic illness affected her career, her energy and the everyday family moments she cherished most. At Mayo Clinic, she found a new treatment approach and renewed hope for the future.
Learn more about her treatment: https://t.co/Tr8A1yLj5I
@JHashashMD | @MayoClinicGIHep | @MayoClinicFLGIH
A Joint @RomeFoundation and @IOIBD1 Consensus provides standardized terminology, evaluation strategies, and treatment recommendations for #IBD with #IBS-like symptoms 🔖 in @AGA_Gastro
👉 https://t.co/TvQQpt2I4S
We’re your GI home throughout fellowship and beyond! Unlock more resources, and education to support your GI career by joining AGA for free as a first-year trainee. Apply here: https://t.co/qeF77Jexur.
📣 #CC360 has ⬆️ its 2025 impact factor to 3🏆
🥳Congrats authors, AEs & @CrohnsColitisFn for advancing high quality #MedEd & #IBD care
💻 Submit your manuscript for an impactful 🌎 reach
📲If interested to be an AE (adult & peds IBD, surgery, GastroPsych, PharmD, GastroRD)
Active Crohn’s disease + cancer treatment = complex decisions.
At #CCC2026, experts debated anti-TNF vs IL-23p19 therapy + what matters most when balancing disease control, safety, and patient priorities: https://t.co/QkPIDwl4O5
#IBD#CrohnsDisease
MUST READ📖
Joint @RomeFoundation & @IOIBD1 RAND/UCLA Recommendations for #Evaluation & #Managmt of #IBD with #IBS-like Symptoms @AGA_Gastro
https://t.co/TAfqa31eTZ
📝Nomenclature: IBD with IBS-like symptoms
Evaluation🩺 🧫
Therapies
🥗Diet
💊Drugs💉
🧠Brain gut behavioral tx
🚨 New Publication! 🚨
Excited to share our new article in @JCGjournal:
“Comparison of Ustekinumab and Vedolizumab Effectiveness in Perianal Crohn’s Disease”
Our findings suggest a potential effectiveness benefit of UST over VZD in patients with PCD, with lower rates of fistula-related surgery and antibiotic use.
@JHashashMD@FarrayeIBD@OmarMTag@jensemineriomd
👉 Read the article here:
https://t.co/GGogy3sDAF
Bowel urgency #BU 😖🚽💩is an under recognized debilitating symptom amongst patients with IBD
📻Tune in tomorrow for @AmCollegeGastro virtual grand rounds for a presentation on #BU moderated 👨⚖️ by @ibdtweets
➡️ https://t.co/0Ixps3kK0I
Feeling very grateful to see our study featured in GI & Hepatology News 🙏
This work would not have been possible without the kindness, mentorship, and support of @Alomari_MD , @AsadurRahman87 , @JHashashMD . Truly thankful to learn from such wonderful mentors along the way 🤍